CEO, 10% Owner of Hemispherx Biopharma Inc (HEB, Financial) William A Carter buys 30,000 shares of HEB on 12/07/2009 at an average price of $0.57 a share.
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address. Hemispherx Biopharma Inc has a market cap of $82.29 million; its shares were traded at around $0.62 with and P/S ratio of 310.52. Hemispherx Biopharma Inc had an annual average earning growth of 9.4% over the past 5 years.
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address. Hemispherx Biopharma Inc has a market cap of $82.29 million; its shares were traded at around $0.62 with and P/S ratio of 310.52. Hemispherx Biopharma Inc had an annual average earning growth of 9.4% over the past 5 years.
